204 related articles for article (PubMed ID: 12953137)
1. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma.
Tapprich C; Fenk R; Schneider P; Bernhardt A; Haas R; Kobbe G
Bone Marrow Transplant; 2003 Sep; 32(6):629-31. PubMed ID: 12953137
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
4. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases.
Kornacker M; Luft T; Ho AD; Schaefer HJ
Eur J Haematol; 2005 Mar; 74(3):250-3. PubMed ID: 15693795
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
7. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
[TBL] [Abstract][Full Text] [Related]
8. Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.
Burt RK; Barr W; Oyama Y; Traynor A; Slavin S
J Rheumatol Suppl; 2001 Oct; 64():42-8. PubMed ID: 11642504
[TBL] [Abstract][Full Text] [Related]
9. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
[No Abstract] [Full Text] [Related]
10. Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity.
Ando T; Yujiri T; Tominaga T; Shinya S; Takahashi T; Nomiyama J; Seguchi M; Matsubara A; Fujii Y; Tanizawa Y
Eur J Haematol; 2005 Feb; 74(2):175-9. PubMed ID: 15654912
[TBL] [Abstract][Full Text] [Related]
11. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
12. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
13. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation.
Musso M; Porretto F; Crescimanno A; Polizzi V; Scalone R
Bone Marrow Transplant; 2004 Apr; 33(7):769-71. PubMed ID: 14755320
[TBL] [Abstract][Full Text] [Related]
14. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
Vela-Ojeda J; García-Ruiz-Esparza MA; Padilla-González Y; Gómez-Almaguer D; Gutiérrez-Aguirre CH; Gómez-Rangel D; Morales-Toquero A; Ruiz-Delgado GJ; Delgado-Lamas JL; Ruiz-Argüelles GJ
Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
[TBL] [Abstract][Full Text] [Related]
15. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of multiple myeloma with an allogeneic peripheral blood stem cell transplantation using a non-myeloablative conditioning regimen].
Kmonícek M; Jebavý L; Lánská M; Zák P; Malý J; Maisnar V
Vnitr Lek; 2000 Jul; 46(7):377-83. PubMed ID: 15635796
[TBL] [Abstract][Full Text] [Related]
17. [Second nonmyeloablative allogeneic peripheral blood stem cell transplantation with more immunosuppressive conditioning regimen for the late graft failure of the patient with acute myeloid leukemia].
Tachikawa Y; Abe Y; Choi I; Ohtsuka R; Nagasawa E; Shibata K; Nishimura J; Nawata H; Muta K
Fukuoka Igaku Zasshi; 2005 Nov; 96(11):378-82. PubMed ID: 16502857
[TBL] [Abstract][Full Text] [Related]
18. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
Carella AM; Beltrami G; Corsetti MT; Scalzulli P; Carella AM; Musto P
Haematologica; 2004 Dec; 89(12):1534-6. PubMed ID: 15590410
[TBL] [Abstract][Full Text] [Related]
19. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
Wiesmann A; Einsele H; Kanz L; Dohmen BM
Bone Marrow Transplant; 2005 Jul; 36(1):89-90. PubMed ID: 15895113
[No Abstract] [Full Text] [Related]
20. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
